Mansfield General Hospital-MedCentral Health System — Mansfield, Ohio

Mansfield General Hospital-MedCentral Health System is a clinical research site located in Mansfield, Ohio, United States 44903.

Crixeo Clinical Trials Trust Score: 82/100 (GOOD). This profile has not yet been claimed by the site owner.

Mansfield General Hospital-MedCentral Health System has participated in 4 clinical trials.

Therapeutic areas: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer.

Sponsors: National Cancer Institute (NCI), NSABP Foundation Inc.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Mansfield

Browse all research sites in Ohio · View every site in Mansfield

Sponsor Feasibility Report

Trust Score: 82/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Mansfield General Hospital-MedCentral Health System?

Mansfield General Hospital-MedCentral Health System has a Crixeo Trust Score of 82/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Mansfield General Hospital-MedCentral Health System conducted?

Mansfield General Hospital-MedCentral Health System has 4 clinical trials on record. Their work covers Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer.

Is Mansfield General Hospital-MedCentral Health System accredited by Crixeo Clinical Trials?

Mansfield General Hospital-MedCentral Health System has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Mansfield General Hospital-MedCentral Health System?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.